NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities
Clinical Development Update: NewAmsterdam Pharma is advancing its obicetrapib program, with key data from Phase 3 trials expected in 2025 to support global regulatory filings, including a planned EMA submission by the second half of 2025. The company reported positive results from three pivotal trials that demonstrated significant LDL-C reduction and a favorable safety profile.
Financial Position and Future Plans: With an unaudited cash balance of $835 million at year-end 2024, NewAmsterdam is focused on commercial readiness and scaling up manufacturing for potential product launches. The company aims to share further scientific findings and continue enrollment in ongoing studies throughout 2025.
Trade with 70% Backtested Accuracy
Analyst Views on NAMSW
No data
About the author
NEWAMSTERDAM PHARMA ANNOUNCES INDUCEMENT GRANTS IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4)
Inducement Grants: The Amsterdam Pharma reports on the availability of inducement grants aimed at supporting companies listed under NASDAQ.
Listing Rule 5635(c): The article discusses the implications of NASDAQ Listing Rule 5635(c) concerning inducement grants for companies seeking to attract talent.
NewAmsterdam Pharma Announces Inducement Grants in Compliance with NASDAQ Listing Rule 5635(c)(4)
Inducement Grants: Amsterdam Pharma reports on the availability of inducement grants aimed at supporting companies listed under NASDAQ.
NASDAQ Listing Rule 5635(c)(4): The article discusses the specific NASDAQ listing rule that governs the issuance of inducement grants to attract and retain talent.
NewAmsterdam Pharma Announces Inducement Grants in Compliance with NASDAQ Listing Rule 5635(c)(4)
Inducement Grants: Amsterdam Pharma reports on the availability of inducement grants aimed at supporting companies listed under NASDAQ.
NASDAQ Listing Rule: The report highlights the specific NASDAQ listing rule 5635(c)(4) related to these inducement grants.
Insider at NewAmsterdam Pharma (NAMS.US) Plans to Sell $6.33 Million in Common Stock via Form 144
Company Announcement: New Amsterdam Pharma intends to sell 200,000 shares of its common stock.
Market Value: The total market value of the shares being sold is approximately $6.33 million.
NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer's Disease Biomarkers at AAIC 2025
Obicetrapib's Impact on Alzheimer's Biomarkers: The clinical trial results indicate that obicetrapib significantly reduced levels of plasma p-tau217, a key Alzheimer's disease biomarker, particularly in ApoE4 carriers, suggesting its potential as a preventive treatment for Alzheimer's.
Dual Benefits of Obicetrapib: In addition to lowering LDL cholesterol levels, obicetrapib shows promise in addressing both neurodegenerative and cardiovascular risks, highlighting its unique therapeutic profile in treating patients at risk for these conditions.
NewAmsterdam Pharma Announces Positive Topline Alzheimer's Disease Data from BROADWAY Clinical Trial
Alzheimer's Disease Biomarker Findings: NewAmsterdam Pharma announced that their treatment, obicetrapib, showed significant reductions in Alzheimer's disease biomarkers in a Phase 3 trial, particularly among ApoE4 carriers, indicating potential for AD prevention alongside cardiovascular benefits.
Upcoming Presentation: The full results of the Alzheimer's sub-study will be presented at the Alzheimer's Association International Conference in Toronto in July 2025, highlighting the implications of CETP inhibition in mitigating Alzheimer's disease risk.
NEWAMSTERDAM PHARMA ANNOUNCES INDUCEMENT GRANTS IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4)
Inducement Grants: The Amsterdam Pharma reports on the availability of inducement grants aimed at supporting companies listed under NASDAQ.
Listing Rule 5635(c): The article discusses the implications of NASDAQ Listing Rule 5635(c) concerning inducement grants for companies seeking to attract talent.
NewAmsterdam Pharma Announces Inducement Grants in Compliance with NASDAQ Listing Rule 5635(c)(4)
Inducement Grants: Amsterdam Pharma reports on the availability of inducement grants aimed at supporting companies listed under NASDAQ.
NASDAQ Listing Rule 5635(c)(4): The article discusses the specific NASDAQ listing rule that governs the issuance of inducement grants to attract and retain talent.
NewAmsterdam Pharma Announces Inducement Grants in Compliance with NASDAQ Listing Rule 5635(c)(4)
Inducement Grants: Amsterdam Pharma reports on the availability of inducement grants aimed at supporting companies listed under NASDAQ.
NASDAQ Listing Rule: The report highlights the specific NASDAQ listing rule 5635(c)(4) related to these inducement grants.
Insider at NewAmsterdam Pharma (NAMS.US) Plans to Sell $6.33 Million in Common Stock via Form 144
Company Announcement: New Amsterdam Pharma intends to sell 200,000 shares of its common stock.
Market Value: The total market value of the shares being sold is approximately $6.33 million.
NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer's Disease Biomarkers at AAIC 2025
Obicetrapib's Impact on Alzheimer's Biomarkers: The clinical trial results indicate that obicetrapib significantly reduced levels of plasma p-tau217, a key Alzheimer's disease biomarker, particularly in ApoE4 carriers, suggesting its potential as a preventive treatment for Alzheimer's.
Dual Benefits of Obicetrapib: In addition to lowering LDL cholesterol levels, obicetrapib shows promise in addressing both neurodegenerative and cardiovascular risks, highlighting its unique therapeutic profile in treating patients at risk for these conditions.
NewAmsterdam Pharma Announces Positive Topline Alzheimer's Disease Data from BROADWAY Clinical Trial
Alzheimer's Disease Biomarker Findings: NewAmsterdam Pharma announced that their treatment, obicetrapib, showed significant reductions in Alzheimer's disease biomarkers in a Phase 3 trial, particularly among ApoE4 carriers, indicating potential for AD prevention alongside cardiovascular benefits.
Upcoming Presentation: The full results of the Alzheimer's sub-study will be presented at the Alzheimer's Association International Conference in Toronto in July 2025, highlighting the implications of CETP inhibition in mitigating Alzheimer's disease risk.
